Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers
Por:
Empar Blanco-Canto, M, Monge-Argiles, J, Perez-Cejuela, C, Badia, C, Gabaldon, L, Munoz-Ruiz, C, Sanchez-Paya, J, Gasparini-Berenguer, R and Leiva-Santana, C
Publicada:
1 mar 2017
Resumen:
Aim: To compare the diagnostic validity of NIA-AA criteria, for AD CSF
biomarkers, with our own new criteria. Materials and Methods: Between
2008 and 2011, 170 patients with Mild Cognitive Impairment (MCI) were
included. CSF levels of A beta 1-42, T-tau, P-tau181, and ratios of
T-tau/A beta 1-42 and P-tau181/A beta 1-42 were analyzed. In our
criteria, we considered 3 or more abnormal variables indicative of a
high likelihood of MCI due to AD. Results: After a clinical follow-up of
4.5 +/- 1.2 years, 44 patients remained stable, 95 developed AD, 15
other forms of dementia, 7 died and 9 received other diagnoses. Using
the NIA-AA criteria and our own criteria, the diagnostic validity of the
CSF biomarkers was 58% versus 85%, specificity 84% versus 72%, PPV 82%
versus 79% and NPV 61% versus 79%. Conclusion: The inclusion of the
ratios in diagnostic criteria increases sensitivity and NPV for the
diagnosis of MCI due to AD.
Filiaciones:
:
Hosp Gen Univ Alicante, Dept Neurol, Pintor Baeza Ave 12,8,C Sect, Alicante, Spain
:
Hosp Gen Univ Alicante, Dept Neurol, Pintor Baeza Ave 12,8,C Sect, Alicante, Spain
Perez-Cejuela, C:
Baix Vinalopo Hosp, Neurol Sect, Alicante, Spain
Badia, C:
Denia Marina Salud Reg Hosp, Alicante, Spain
Gabaldon, L:
Denia Marina Salud Reg Hosp, Alicante, Spain
:
Hosp Gen Univ Alicante, Immunol Lab, Alicante, Spain
:
Hosp Gen Univ Alicante, Dept Prevent Med, Alicante, Spain
:
Hosp Gen Univ Alicante, Dept Neurol, Pintor Baeza Ave 12,8,C Sect, Alicante, Spain
:
Hosp Gen Univ Alicante, Dept Neurol, Pintor Baeza Ave 12,8,C Sect, Alicante, Spain
|